[go: up one dir, main page]

WO1994019324A1 - Process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate - Google Patents

Process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate Download PDF

Info

Publication number
WO1994019324A1
WO1994019324A1 PCT/EP1994/000517 EP9400517W WO9419324A1 WO 1994019324 A1 WO1994019324 A1 WO 1994019324A1 EP 9400517 W EP9400517 W EP 9400517W WO 9419324 A1 WO9419324 A1 WO 9419324A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridoxine
oxo
pyrrolidone carboxylate
preparation
isopropanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1994/000517
Other languages
English (en)
French (fr)
Inventor
Massimo Baldacci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratori Baldacci SpA
Original Assignee
Laboratori Baldacci SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratori Baldacci SpA filed Critical Laboratori Baldacci SpA
Publication of WO1994019324A1 publication Critical patent/WO1994019324A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • C07D213/66One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C07D213/672-Methyl-3-hydroxy-4,5-bis(hydroxy-methyl)pyridine, i.e. pyridoxine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/282-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles

Definitions

  • the present invention refers to a process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate having the formula:
  • Pyridoxine 5-oxo-2-pyrrolidone carboxylate is a known substance used for many years for therapeutic purposes.
  • Pyridoxine also known as Bg vitamin
  • Bg vitamin is a well-known active principle that found use, among others, in the treatment of acute alcoholic intoxications, although with certain perplexities as to its real benefit in therapeutic treatments.
  • vomiting states and those of hyperprolactinemias induced by neuroendocrine disorderliness from iatrogenic origin are also noteworthy.
  • Patent No. 1.131.855 that involves reacting under heat and stirring for 30 minutes, solutions, preferably in ethanol, of pyridoxine and pyroglutamic acid, precipitating thereafter by cooling the crude reaction product. The latter is then subjected to a purification by chromatography on an ion exchange resin, finally isolating the desired product by precipitation of the residue, obtained by means of evaporation under reduced pressure of the eluate from ethanol.
  • Main object of the present invention is to provide a process for preparing the subject product which should prove to be industrially advantageous, both from yield standpoint and easy production procedure.
  • the present invention entails a process for preparing pyridoxine
  • the salt formation obtained therefrom is confirmed by the melting point and by the I.R. spectrum that shows characteristic absorption bands of a salt that are different from those of the two starting compounds.
  • the DSC spectrum confirms the formation of the desired salt.
  • the salt obtained has a molecular weight of 298.28 and the following per cent composition: C:52,34%, H:6,08%, N:9,33% and O:32,18%, has the aspect of a white odourless crystalline powder, having a melting point of 96-98°C and having a slightly acidic taste, very water-soluble, poorly soluble in cold ethyl alcohol and insoluble in common organic solvents, such as acetone, ethyl ether, chloroform and benzene.
  • EXAMPLE 8 663 kg of l,2-pyrrolidone-5-carboxylic acid and 11,337 kg of pyridoxine base are thoroughly sieved and mixed for 30 minutes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
PCT/EP1994/000517 1993-02-23 1994-02-19 Process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate Ceased WO1994019324A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI93A000340 1993-02-23
ITMI930340A IT1263956B (it) 1993-02-23 1993-02-23 Procedimento per la preparazione di 5-oxo-2-pirrolidoncarbossilato di piridossina

Publications (1)

Publication Number Publication Date
WO1994019324A1 true WO1994019324A1 (en) 1994-09-01

Family

ID=11365118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/000517 Ceased WO1994019324A1 (en) 1993-02-23 1994-02-19 Process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate

Country Status (5)

Country Link
KR (1) KR100257967B1 (it)
AT (1) AT403160B (it)
IT (1) IT1263956B (it)
TW (1) TW235962B (it)
WO (1) WO1994019324A1 (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105906559B (zh) * 2016-06-14 2018-08-14 成都倍特药业有限公司 一种药用级美他多辛的一步合成法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6990M (it) * 1968-03-13 1969-05-27
FR2244466A1 (en) * 1973-06-29 1975-04-18 Dufour Claude Salts of pyridoxine with aryloxy alkanoic acids - useful as antihyperlipemic agents for oral administration
FR2260330A1 (en) * 1974-02-07 1975-09-05 Innothera Lab Sa Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index
FR2485372A1 (fr) * 1980-06-30 1981-12-31 Baldacci Lab Spa Composition pharmaceutique pour le traitement des etats d'intoxication alcoolique aigue a base de 5-oxo-2-pyrrolidone carboxylate de pyridoxine et procede de preparation de ce dernier

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) * 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6990M (it) * 1968-03-13 1969-05-27
FR2244466A1 (en) * 1973-06-29 1975-04-18 Dufour Claude Salts of pyridoxine with aryloxy alkanoic acids - useful as antihyperlipemic agents for oral administration
FR2260330A1 (en) * 1974-02-07 1975-09-05 Innothera Lab Sa Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index
FR2485372A1 (fr) * 1980-06-30 1981-12-31 Baldacci Lab Spa Composition pharmaceutique pour le traitement des etats d'intoxication alcoolique aigue a base de 5-oxo-2-pyrrolidone carboxylate de pyridoxine et procede de preparation de ce dernier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105906559B (zh) * 2016-06-14 2018-08-14 成都倍特药业有限公司 一种药用级美他多辛的一步合成法

Also Published As

Publication number Publication date
ITMI930340A0 (it) 1993-02-23
KR940019703A (ko) 1994-09-14
AT403160B (de) 1997-11-25
ITMI930340A1 (it) 1994-08-23
ATA900494A (de) 1997-04-15
KR100257967B1 (ko) 2000-07-01
TW235962B (it) 1994-12-11
IT1263956B (it) 1996-09-05

Similar Documents

Publication Publication Date Title
CA1331616C (en) Organic salts of physostigmine derivative
JPH11514323A (ja) ジニトラミド酸及びそれらの塩類の製造方法
JPH08506332A (ja) テトラゾール−5−カルボン酸誘導体の製法
NO163367B (no) Fremgangsmaate ved fremstilling av 2-alkoxy-n-(1-azabicyclo(2,2,2)octan-3-yl)amino-benzamider.
US4284797A (en) Process for separating mixtures of 3- and 4-nitrophthalic acid
WO1994019324A1 (en) Process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate
US20050272775A1 (en) Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
EP0611369B1 (en) Process for preparing (s) (+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)
CN109053808B (zh) 一种高纯度双环铂针状晶体的工业化制备方法
KR100336247B1 (ko) 7-[7-(s)-아미노-5-아자스피로[2,4]헵탄-5-일]-8-클로로-6-플루오로-1-[(1r,2s)-2-플루오로사이클로프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산의무수물,및이의3/2수화물의선택적수득방법
CN119118888A (zh) 巯基琥珀酸甜菜碱1:1的新制备方法
US4052451A (en) Preparation of calcium pantothenate
CN114031607B (zh) 一种德拉沙星及其中间体的精制方法
US6455727B1 (en) Process for preparing carbetapentane tannate
US7550628B2 (en) Process for preparing phenolic acid salts of gabapentin
RU2102380C1 (ru) Нитраты n-алканолсукцинамидов или имидов, способ их получения, n-алканолсукцинамиды или имиды
KR100204532B1 (ko) 피리독신 5-옥소-2-피롤리돈 카르복실레이트의 제조방법
CN116621721B (zh) 一种壬二酰胺的制备方法
CN111018692B (zh) 以超强碱法制备1,2,3,4-四氢-1-萘甲酸的方法
JP3452329B2 (ja) 3−メチル−1−フェニルホスホレンオキシドの製造方法
US4174451A (en) 2-Furyl-(3,4-dimethyl-2-pyridyl)-carbinol
JPS6014026B2 (ja) パンテテイン−s−スルホン酸及びその塩の製造法
SU1583418A1 (ru) Способ получени 2-амино-4,6-диметилпиримидина
US20070123565A1 (en) Donepezil Hydrochloride Form VI
CN110857303A (zh) 一种西格列汀游离碱单体的制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT CZ HU PL SK

ENP Entry into the national phase

Ref country code: AT

Ref document number: 1994 9004

Date of ref document: 19940901

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 19949004

Country of ref document: AT